Core Viewpoint - LEEF Brands, Inc. is increasing its private placement offering to issue up to 7,600,000 units at a price of C$0.25 per unit, aiming for gross proceeds of up to C$1.9 million [1][5]. Group 1: Offering Details - Each unit will consist of one common share and one common share purchase warrant, with each warrant allowing the purchase of an additional common share at C$0.30 for 24 months [2]. - The offering is conducted under the listed issuer financing exemption, meaning the securities issued will not be subject to a statutory hold period under Canadian securities laws [3]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be used for general working capital, supporting operations from the successful harvest at Salisbury Canyon Ranch, and accelerating operations in New York [4]. Group 3: Management Commentary - The CEO of LEEF Brands stated that the increased financing reflects investor confidence and positions the company for expansion in extraction operations, enhancing vertical integration and exploring new revenue streams [5]. Group 4: Company Overview - LEEF Brands Inc. is a leading extraction and manufacturing cannabis company based in California and New York, with a comprehensive supply chain and innovative manufacturing processes [6].

Core Insights - Aurora Cannabis Inc. is launching its Whistler Cannabis Co. brand in Australia, expanding its global footprint and offering Australian patients access to premium Canadian cannabis products [1][2][3] - The company emphasizes its commitment to quality and patient care, leveraging its Canadian cultivation expertise to ensure consistent product quality [2][3] Product Launch Details - The first two products from Whistler Cannabis Co. to be introduced in Australia are Ginger Breath and Critical Diesel, both featuring high THC content [7] - Ginger Breath has a THC level of 32% and is an Indica strain, while Critical Diesel has a THC level of 28% and is a Sativa strain [7] Company Background - Aurora Cannabis Inc. is a leading global medical cannabis company headquartered in Edmonton, Alberta, with a diverse portfolio of brands serving both medical and consumer markets across multiple regions [4][5] - The company is recognized for its robust regulatory expertise and commitment to science and innovation, which supports its success in international markets [3][4]

Market Expansion - Cannabis-infused drinks on draft are now available in 3 states [1]

Group 1 - Cronos Group Inc. (NASDAQ: CRON) stock price increased by 15% on news that President Trump’s administration will consider rescheduling cannabis in the coming weeks [1] - The announcement has implications for Canadian cannabis licensed producers (LPs) and U.S. cannabis Multi-State Operators [1] Group 2 - The article is part of a monthly report on the cannabis industry, highlighting the author's expertise in technical stock analysis, option strategies, small cap strategies, and emerging markets [1]

Brandon Gomez, tell us more about cannabis stocks today. Hey, Scott. Yeah, look, it was a massive surge in cannabis names.We've been here before, though. Trump once again voicing his support to reclassify cannabis as a less dangerous drug. Now, this would align it with steroids or Tylenol with codine rather than more dangerous drugs like heroin LSD.Now, it could blaze a new trail for the industry, but investors shouldn't light up with celebration just yet. Despite Trump saying today that a decision could co ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - Canopy Growth (NASDAQ: CGC) experienced a 24% increase in stock price following President Trump's announcement regarding the potential rescheduling of cannabis in the upcoming weeks, indicating a significant opportunity for expansion into the U.S. cannabis market [1]. Group 1: Company Insights - Canopy Growth is strategically positioned to expand into U.S. cannabis markets through its subsidiary, Canopy USA [1]. Group 2: Industry Context - The announcement from the Trump administration suggests a potential shift in cannabis regulation, which could benefit Canadian licensed producers (LPs) like Canopy Growth [1].

Regulatory Landscape & Policy Changes - The cannabis industry has been actively lobbying Washington, potentially leading to more favorable policies [2] - The Trump administration expressed support for cannabis and reducing uncertainty in the sector [2] - Rescheduling cannabis from Schedule I to Schedule III would significantly alter the industry's tax structure [2][4] - The FDA has acknowledged the medicinal use of cannabis in a 28-page memo [3] Market Dynamics & Investment Opportunities - State-by-state, cannabis legalization is consistently progressing, with adult, medical, and recreational markets being approved [6] - The cannabis market is estimated to be an $80 billion market, including adult, medical, and illicit sales [8] - Top-line growth is evident, attracting consumers seeking exposure to this growth [8] - Investing in the cannabis sector now allows investors to be ahead of institutional capital [8] Challenges & Considerations - Confusion exists regarding the business outlook due to complex legal and regulatory frameworks at both state and federal levels [5] - Restrictions on sales types vary across states where cannabis products are available [5] - Hemp-derived THC legalization through the farm bill adds complexity for investors [7] - Investing in the sector can be complicated, requiring a deep understanding of the industry [8]

Core Viewpoint - Vext Science, Inc. is set to announce its financial results for Q2 2025 on August 20, 2025, before market open, and will host a conference call to discuss these results [1][2]. Company Overview - Vext Science, Inc. operates as a U.S.-based cannabis company with vertical operations in Arizona and Ohio, focusing on cultivation, manufacturing, and retail [4]. - The company owns state-of-the-art cultivation and manufacturing facilities, as well as dispensaries in its key markets [4]. - Vext manufactures Vapen™, a leading brand of THC concentrates, edibles, and distillate cartridges in Arizona, utilizing high-quality in-house flower [4]. - The leadership team has a proven track record in building and operating profitable multi-state operations, with a focus on growth in Arizona and Ohio [4]. Financial Communication - The financial results for Q2 2025 will be released before the market opens on August 20, 2025, followed by a conference call at 8:00 a.m. ET [1][2]. - Participants can join the call via specific dial-in numbers, and a replay will be available afterward on Vext's investor website [3].

Group 1 - Alan Brochstein is a pioneer in the cannabis investment sector, having focused exclusively on this industry since 2007 [1] - He founded AB Analytical Services to provide independent consulting to registered investment advisors [1] - Alan is the managing partner of New Cannabis Ventures, which has been a key provider of financial information in the cannabis industry since 2015 [1] Group 2 - Alan has led the investing group 420 Investor since 2013, which focuses on publicly-traded cannabis stocks [2] - The group covers 20 stocks, providing investment news, earnings report previews, and post-report analyses [2] - Additional features of the group include a model portfolio, 10 weekly videos with chart analysis, 3 weekly summary pieces, a monthly newsletter, and a chat for questions [2]